Bernd Winterhalter
Corporate Officer/Principal at CureVac SE
Profile
Bernd Winterhalter is currently the Chief Development Officer at CureVac SE since 2019.
Prior to this, he worked as the Executive Medical Director at Bristol-Myers Squibb GmbH & Co. KGaA from 2004 to 2018 and as the Vice President-Medical, Science & Health Economics at Pharmacia GmbH from 1997 to 2003.
He also briefly served as the Chief Development Officer at CureVac NV from 2019 to 2021.
Dr. Winterhalter holds a doctorate degree from the University of Freiburg.
Bernd Winterhalter active positions
| Companies | Position | Start |
|---|---|---|
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | 2019-11-30 |
Former positions of Bernd Winterhalter
| Companies | Position | End |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 2021-01-31 |
Bristol-Myers Squibb GmbH & Co. KGaA
 Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The private company is based in Munich, Germany. The CEO of the company is Han Steutel. | Chief Tech/Sci/R&D Officer | 2017-12-31 |
| Pharmacia GmbH | Chief Tech/Sci/R&D Officer | 2002-12-31 |
Training of Bernd Winterhalter
| University of Freiburg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Private companies | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
| Pharmacia GmbH | |
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The private company is based in Munich, Germany. The CEO of the company is Han Steutel. | Health Technology |
- Stock Market
- Insiders
- Bernd Winterhalter
